Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - Change of Director's Interest Notice - P Meyers (ASX:IMM)

To view the notice, download the attached PDF.

Immutep - Change of Director's Interest Notice - R Howard (ASX:IMM)

To view the notice, download the attached PDF.

Application for quotation of securities - IMM (ASX:IMM)

To view the application, download the attached PDF.

Immutep - Notification regarding unquoted securities - IMM (ASX:IMM)

To view the notification, download the attached PDF.

Notification regarding unquoted securities - IMM (ASX:IMM)

To view the notification, download the attached PDF.

Proposed issue of securities - IMM (ASX:IMM)

To view the notification, download the attached PDF.

Immutep - Commercial Scale in Manufacturing of Efti Achieved (ASX:IMM)

SYDNEY, AUSTRALIA – 8 December, 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nov...read more

Immutep - GMP Manufacturing Process Developed for IMP761 LAG-3 Agonist (ASX:IMM)

SYDNEY, AUSTRALIA – 06 December 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nov...read more

Immutep enters 2nd collaboration with Pfizer and Merck KGaA (ASX:IMM)

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Efti...read more

Immutep - Results of Meeting (ASX:IMM)

SYDNEY, AUSTRALIA – 23 November 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) advises that the results of its Annual General Meeting...read more

Immutep AGM 2022 - CEO's Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep AGM 2022 - Chairman's Address (ASX:IMM)

23 November 2022 Dear Fellow Shareholders, It’s my pleasure to welcome you to Immutep Limited’s Annual General Meeting for the financial year 2022. I’m delighted that we...read more

Immutep Investor Update (ASX:IMM)

Message from the CEO At the heart of all Immutep’s scientific endeavours is collaboration to build value for our shareholders and to benefit patients. Many of our ideas and assets are ...read more

Immutep receives A$1 million R&D Tax Incentive (ASX:IMM)

SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$986,286 cash rebate from the A...read more

Immutep - INSIGHT-003 triple combination data presented at SITC 2022 (ASX:IMM)

SYDNEY, AUSTRALIA – 11 November 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nov...read more

Viewing: 121 - 135 of 200 Previous | Next